Kapitalo Investimentos Ltda Invests $499,000 in Chemed Co. (NYSE:CHE)

Kapitalo Investimentos Ltda purchased a new position in shares of Chemed Co. (NYSE:CHEFree Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 853 shares of the company’s stock, valued at approximately $499,000.

Other large investors have also recently added to or reduced their stakes in the company. Mitsubishi UFJ Trust & Banking Corp raised its stake in shares of Chemed by 43.1% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 667 shares of the company’s stock worth $347,000 after buying an additional 201 shares in the last quarter. UBS Group AG raised its position in Chemed by 6.8% in the third quarter. UBS Group AG now owns 34,221 shares of the company’s stock worth $17,785,000 after acquiring an additional 2,178 shares in the last quarter. Loomis Sayles & Co. L P lifted its holdings in Chemed by 25.8% in the third quarter. Loomis Sayles & Co. L P now owns 29,294 shares of the company’s stock valued at $15,224,000 after acquiring an additional 6,013 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Chemed by 2.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,431 shares of the company’s stock worth $1,783,000 after purchasing an additional 94 shares in the last quarter. Finally, Kestra Advisory Services LLC boosted its position in shares of Chemed by 3.8% during the 3rd quarter. Kestra Advisory Services LLC now owns 634 shares of the company’s stock worth $329,000 after purchasing an additional 23 shares in the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.

Chemed Trading Down 0.3 %

Shares of CHE stock traded down $1.38 during mid-day trading on Tuesday, reaching $537.66. The stock had a trading volume of 5,237 shares, compared to its average volume of 80,232. Chemed Co. has a 12-month low of $492.84 and a 12-month high of $654.62. The business has a 50-day simple moving average of $570.54 and a 200 day simple moving average of $591.38. The company has a market cap of $8.14 billion, a P/E ratio of 28.99, a price-to-earnings-growth ratio of 2.22 and a beta of 0.46.

Chemed (NYSE:CHEGet Free Report) last posted its earnings results on Wednesday, April 24th. The company reported $4.68 earnings per share for the quarter, missing the consensus estimate of $5.09 by ($0.41). Chemed had a net margin of 12.36% and a return on equity of 30.52%. The business had revenue of $589.23 million for the quarter, compared to analysts’ expectations of $587.18 million. Research analysts anticipate that Chemed Co. will post 21.54 EPS for the current year.

Chemed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 18th. Investors of record on Thursday, May 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date of this dividend is Thursday, May 30th. Chemed’s payout ratio is currently 8.61%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Royal Bank of Canada cut their price target on shares of Chemed from $712.00 to $697.00 and set an “outperform” rating for the company in a report on Tuesday, May 21st. StockNews.com raised shares of Chemed from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Finally, Oppenheimer boosted their price target on Chemed from $625.00 to $650.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th.

Get Our Latest Stock Analysis on CHE

Insider Activity at Chemed

In other news, Director Patrick P. Grace sold 284 shares of the business’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $540.98, for a total value of $153,638.32. Following the completion of the transaction, the director now directly owns 3,270 shares of the company’s stock, valued at $1,769,004.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Chemed news, Director Patrick P. Grace sold 284 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $540.98, for a total transaction of $153,638.32. Following the sale, the director now directly owns 3,270 shares of the company’s stock, valued at approximately $1,769,004.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin J. Mcnamara sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $544.17, for a total transaction of $816,255.00. Following the completion of the transaction, the chief executive officer now directly owns 107,049 shares of the company’s stock, valued at approximately $58,252,854.33. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,592 shares of company stock valued at $13,424,584. 3.32% of the stock is owned by corporate insiders.

About Chemed

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Further Reading

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHEFree Report).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.